Ralimetinib dimesylate
Code | Size | Price |
---|
TAR-T6047-2mg | 2mg | £114.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6047-5mg | 5mg | £132.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6047-1mL | 1 mL * 10 mM (in DMSO) | £152.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6047-10mg | 10mg | £178.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6047-25mg | 25mg | £281.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6047-50mg | 50mg | £451.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6047-100mg | 100mg | £490.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Ralimetinib Mesylate is the dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities.
CAS:
862507-23-1
Formula:
C26H37FN6O6S2
Molecular Weight:
612.74
Pathway:
Autophagy; Apoptosis; MAPK
Purity:
0.9938
SMILES:
CS(O)(=O)=O.CS(O)(=O)=O.CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C
Target:
Apoptosis; p38 MAPK; Autophagy
References
Ishitsuka K, et al. Br J Haematol, 2008, 141(5), 598-606.
Chiang C, Zhang M, Wang D, et al. Therapeutic potential of targeting MKK3-p38 axis with Capsaicin for Nasopharyngeal Carcinoma. Theranostics. 2020, 10(17): 7906.
Mader M, et al. Bioorg Med Chem Lett, 2008, 18(1), 179-183.
Ishitsuka K, et al. Oncogene, 2005, 24(38), 5888-5896.
Dong W, Xie W, Liu Y, et al. Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways[J]. Antiviral Research. 2020, 173: 104651.
Chiang C, Zhang M, Wang D, et al. Therapeutic potential of targeting MKK3-p38 axis with Capsaicin for Nasopharyngeal Carcinoma[J]. Theranostics. 2020, 10(17): 7906.
Dong W, Xie W, Liu Y, et al. Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways. Antiviral Research. 2020, 173: 104651